Lyra Therapeutics Inc (LYRA) Stock: A Review of the Recent Movement

The stock of Lyra Therapeutics Inc (LYRA) has seen a -8.93% decrease in the past week, with a -1.41% drop in the past month, and a 7.06% flourish in the past quarter. The volatility ratio for the week is 9.90%, and the volatility levels for the past 30 days are at 8.39% for LYRA. The simple moving average for the past 20 days is -5.74% for LYRA’s stock, with a 35.20% simple moving average for the past 200 days.

Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?

The 36-month beta value for LYRA is also noteworthy at 0.23. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The public float for LYRA is 43.67M, and at present, short sellers hold a 0.47% of that float. The average trading volume of LYRA on April 03, 2024 was 328.83K shares.

LYRA) stock’s latest price update

The stock of Lyra Therapeutics Inc (NASDAQ: LYRA) has decreased by -10.24 when compared to last closing price of 6.25.Despite this, the company has seen a loss of -8.93% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-28 that Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Analysts’ Opinion of LYRA

Many brokerage firms have already submitted their reports for LYRA stocks, with BTIG Research repeating the rating for LYRA by listing it as a “Buy.” The predicted price for LYRA in the upcoming period, according to BTIG Research is $15 based on the research report published on October 06, 2023 of the previous year 2023.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $12. The rating they have provided for LYRA stocks is “Buy” according to the report published on August 31st, 2023.

Cantor Fitzgerald gave a rating of “Overweight” to LYRA, setting the target price at $15 in the report published on May 24th of the previous year.

LYRA Trading at 4.57% from the 50-Day Moving Average

After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.38% of loss for the given period.

Volatility was left at 8.39%, however, over the last 30 days, the volatility rate increased by 9.90%, as shares sank -2.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.88% upper at present.

During the last 5 trading sessions, LYRA fell by -8.93%, which changed the moving average for the period of 200-days by +92.78% in comparison to the 20-day moving average, which settled at $5.95. In addition, Lyra Therapeutics Inc saw 7.06% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LYRA starting from Waksal Harlan, who purchase 25,000 shares at the price of $2.96 back on Nov 10 ’23. After this action, Waksal Harlan now owns 261,966 shares of Lyra Therapeutics Inc, valued at $74,095 using the latest closing price.

PERCEPTIVE ADVISORS LLC, the Director of Lyra Therapeutics Inc, purchase 3,610,832 shares at $2.49 during a trade that took place back on May 31 ’23, which means that PERCEPTIVE ADVISORS LLC is holding 11,469,117 shares at $8,999,999 based on the most recent closing price.

Stock Fundamentals for LYRA

Current profitability levels for the company are sitting at:

  • -43.08 for the present operating margin
  • -14.11 for the gross margin

The net margin for Lyra Therapeutics Inc stands at -40.23. The total capital return value is set at -0.55. Equity return is now at value -73.67, with -49.63 for asset returns.

Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -2.35. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 62.61.

Currently, EBITDA for the company is -65.25 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 218.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.35.


In summary, Lyra Therapeutics Inc (LYRA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts